Neuropharmacology · Nov 16, 2026

Metabolic, Hepatic, and Neuropathological Effects of Palm11-PrRP31 and Liraglutide in High-Fat Diet-Fed APP/PS1 Mice

By Mengr A, Sopko Z, Vaculová P et al.

Metabolic stress is known to accelerate Alzheimer’s disease (AD) progression. In our previous study, we demonstrated that long-term high-fat diet (HFD) feeding exacerbated not only amyloid-β (Aβ) burden but also liver steatosis in APP/PS1 mice, a transgenic model of AD, with effects worsening with age. The present study investigated whether a three-month treatment (from 6 to 9 months of age) with anorexigenic peptides (palm¹¹-PrRP31 or liraglutide) could attenuate AD-like pathology, neuroinflammation, liver steatosis, and Aβ clearance in APP/PS1 male mice on HFD. The two compounds exhibited distinct therapeutic effects. Liraglutide reduced body weight and improved glucose tolerance in both genotypes, while also attenuating insulin resistance in APP/PS1 mice. In contrast, palm¹¹-PrRP31 significantly reduced Aβ plaque burden and showed a tendency to decrease astrocytosis. Notably, both peptides markedly reduced microgliosis and pathological tau phosphorylation at Ser202 and Thr205 in the hippocampus and cerebral cortex. HFD induced pronounced hepatic steatosis in both genotypes; however, APP/PS1 mice exhibited more severe lipid imbalance, characterized by increased triacylglycerols and decreased phospholipids and cardiolipins compared to wild-type controls. While both compounds reduced liver steatosis and inflammation in wild-type mice, only liraglutide normalized lipid composition in APP/PS1 mice. Furthermore, Aβ deposits colocalized with CD11b clusters were absent in the liver of liraglutide-treated APP/PS1 mice. In conclusion, both peptides exert neuroprotective effects under metabolic stress, but through distinct mechanisms. Palm¹¹-PrRP31 primarily reduces amyloid pathology and neuroinflammation, whereas liraglutide acts mainly through metabolic improvement.

doi.org/10.1016/j.neuropharm.2026.111263PubMed 43039332Interventions

AgingResearch.News